Side-by-side · Research reference
5-Amino-1MQvsCagrilintide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED8/38 cited
BPhase 3HUMAN-REVIEWED35/64 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
01Mechanism of Action
Parameter
5-Amino-1MQ
Cagrilintide
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Feedback intact?
—
Yes — acts via physiological amylin pathways
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Cagrilintide
Lower / starter dose
50 mg / day
—
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Form
Oral capsule
—
Timing
Morning fasted preferred
—
Half-life
Hours (estimated; no human PK published)
—
Standard dose (combination)
—
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
Monotherapy dosing
—
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
03Metabolic / Fat Loss Evidence
Parameter
5-Amino-1MQ
Cagrilintide
Weight loss vs semaglutide
—
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
Absolute weight change
—
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
Glycemic benefit
—
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
Body composition
—
Predominant fat loss with weight reduction
Mitochondrial function
—
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
Key publications
—
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
04Side Effects & Safety
Parameter
5-Amino-1MQ
Cagrilintide
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
—
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Gastrointestinal
—
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
Injection site reactions
—
Local reactions possible with subcutaneous administration
Safety profile
—
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
Tolerability
—
Tolerability considerations similar to GLP-1RAs
Muscle preservation
—
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
05Administration Protocol
Parameter
5-Amino-1MQ
Cagrilintide
1. Form
Oral capsule. No injection.
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
2. Administration
Take with water, fasted preferred.
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
3. Timing
Morning fasted.
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
4. Storage
Room temp ≤25 °C, dry place.
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
5. Caveat
Monitor B-vitamin status with chronic use.
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
06Stack Synergy
5-Amino-1MQ
— no documented stacks
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation